Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

drug alertDecember 14 2015

A drug alert concerning Pfizer’s Genotropin GoQuick pre-filled pens, containing somatropin 5.3mg or 12mg powder for solution for injection, has been issued. However, to avoid product shortages, the products are not being recalled.

The problem relates to a manufacturing defect for the dosing mechanism of some of the pens. “The defect has been found to create the possibility of the dose being set to one extra click beyond the dose selected and indicated in the memory window when the patient turns the dose knob with excessive force,” said the alert issued on December 9.

“This may result in a small increase in the dosage administered compared to the preset dose:

  • an additional 0.05mg of Genotropin for the 5.3mg Go Quick pre-filled pen;
  • an additional 0.15mg of Genotropin for the 12mg GoQuick pre-filled pen.”

All unexpired batches, but not all pens within the batches, may be affected. “Healthcare professionals are asked to remind patients to follow the instruction to align the dose settings in order to avoid the potential for an incorrect dose being administered.”

If any patient becomes aware that their device may be defective, health professionals are asked to contact Pfizer’s endocrine helpline on 0800 521249 or email This email address is being protected from spambots. You need JavaScript enabled to view it., or to contact Pfizer Medical Information on 01304 616161.

Link:

MHRA Drug Alert (EL(15)a/12)

July 31 2018 General practices employing pharmacists are citing improved capacity to see patients and workload changes as the main benefits of the scheme.
July 25 2018 Switching to sulfonylureas in type 2 diabetes has been linked with an increased risk of complications compared with staying on metformin, a BMJ study has concluded. However, the study has...